Tenaya Therapeutics shares surge 14.34% after-hours as positive clinical data and DSMB support advance gene therapy trials.

Tenaya Therapeutics surged 14.34% in after-hours trading following the release of third-quarter 2025 financial results and clinical updates. The company reported positive interim data from its MyPEAK-1 trial for TN-201 gene therapy, including durable, dose-dependent MyBP-C protein increases and improved hypertrophy measures in MYBPC3-associated HCM patients. The Data Safety Monitoring Board endorsed dose expansion for both TN-201 and TN-401 programs, while the RIDGE-1 trial for TN-401 reached key dosing milestones. Additionally, reduced R&D and G&A expenses, coupled with a $56.3M cash balance sufficient for operations through mid-2026, reinforced investor confidence. These developments, highlighting therapeutic progress and financial discipline, directly drove the post-market rally.